Oxeia CEO Michael Wyand participated in OneNucleus BioWednesday Webinar: Prevention vs. Cure

Written By Holly Plante
Watch here
Holly Plante
Previous

Public Service Announcement: Phase 2 clinical trial for Oxeia’s concussion drug, OXE103
Next

One Nucleus: Dr. Michael Wyand to participate in panel